Figure 4 | Scientific Reports

Figure 4

From: TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin

Figure 4

Auranofin/TUSC2/erlotinib inhibits tumor growth and prolong animal survival significantly.

A subcutaneous mouse model of the human NSCLC using H1299 cells was adopted to evaluate effect the trinary combination: Auranofin plus systemic delivery of DC-based TUSC2 nanoparticles, and erlotinib. (A) Tumor volumes were calculated taking length of the longest diameter across the tumor and with width of the corresponding perpendicular diameter using the formula: length x width2 × 0.52. The rate of tumor growth inhibition was calculated as 100% × (treated tumor size/control tumor size). (B) Mice were weighed throughout the experiments. (C) Overall survival of animals with various treatments were estimated by Kaplan-Meier method. Log-rank (Mantel-Cox) test was performed to compare overall survival between TUSC2/erlotinib treated mice and TUSC2/erlotinib/Auranofin treated mice (P < 0.0001).

Back to article page